Cargando…

Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools

Juvenile Dermatomyositis (JDM) is a systemic immune-mediated disease of childhood, characterized by muscle weakness, and a typical skin rash. Other organ systems and tissues such as the lungs, heart, and intestines can be involved, but may be under-evaluated. The inflammatory process in JDM is chara...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wienke, Judith, Deakin, Claire T., Wedderburn, Lucy R., van Wijk, Femke, van Royen-Kerkhof, Annet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305419/ https://www.ncbi.nlm.nih.gov/pubmed/30619311 http://dx.doi.org/10.3389/fimmu.2018.02951

Ejemplares similares

Anti–Cytosolic 5′‐Nucleotidase 1A Autoantibodies Are Absent in Juvenile Dermatomyositis
por: Rietveld, Anke, et al.
Publicado: (2021)

Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis
por: Wienke, Judith, et al.
Publicado: (2020)

Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2021)

PReS-FINAL-2131: Hunting for biomarkers in juvenile dermatomyositis
por: Bellutti Enders, F, et al.
Publicado: (2013)

Treatment of refractory juvenile dermatomyositis with tacrolimus
por: Hassan, J, et al.
Publicado: (2008)

Consensus-based recommendations for the management of juvenile dermatomyositis
por: Enders, Felicitas Bellutti, et al.
Publicado: (2017)

CD4(+)FOXP3(+) regulatory T cells are abundantly present in inflamed muscle of patients with juvenile dermatomyositis
por: Vercoulen, Yvonne, et al.
Publicado: (2011)

CD4(+)FOXP3(+) regulatory T cells are abundantly present in inflamed muscle of patients with juvenile dermatomyositis
por: Vercoulen, Yvonne, et al.
Publicado: (2011)

Galectin‐9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation
por: Wienke, Judith, et al.
Publicado: (2019)

SHARE – workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile dermatomyositis
por: Enders, Felicitas Bellutti, et al.
Publicado: (2014)

Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
por: Campanilho-Marques, Raquel, et al.
Publicado: (2020)

Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study
por: van Dijkhuizen, E. H. Pieter, et al.
Publicado: (2018)

Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling
por: Deakin, Claire T., et al.
Publicado: (2018)

T cell interaction with activated endothelial cells primes for tissue-residency
por: Wienke, Judith, et al.
Publicado: (2022)

Design of the muscles in motion study: a randomized controlled trial to evaluate the efficacy and feasibility of an individually tailored home-based exercise training program for children and adolescents with juvenile dermatomyositis
por: Habers, Esther A, et al.
Publicado: (2012)

Increased Presence of FOXP3(+) Regulatory T Cells in Inflamed Muscle of Patients with Active Juvenile Dermatomyositis Compared to Peripheral Blood
por: Vercoulen, Yvonne, et al.
Publicado: (2014)

Maternal microchimerism in muscle biopsies from children with juvenile dermatomyositis
por: Ye, Yi, et al.
Publicado: (2012)

Comparison of the utility and validity of three scoring tools to detect skin disease in patients with juvenile dermatomyositis
por: Campanilho-Marques, Raquel, et al.
Publicado: (2014)

Being on the juvenile dermatomyositis rollercoaster: a qualitative study
por: Livermore, Polly, et al.
Publicado: (2019)

Calcinosis in juvenile dermatomyositis: Updates on pathogenesis and treatment
por: Pinotti, Caitlan S., et al.
Publicado: (2023)

Regulatory B cell Il-10 production is diminished in juvenile dermatomyositis
por: Piper, Christopher, et al.
Publicado: (2014)

Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research
por: McCann, Liza J, et al.
Publicado: (2018)

Proposal for the development of an international minimal data collection for juvenile dermatomyositis (JDM)
por: McCann, Liza J, et al.
Publicado: (2011)

Mapping the current psychology provision for children and young people with juvenile dermatomyositis
por: Livermore, Polly, et al.
Publicado: (2021)

Clinically inactive disease in juvenile dermatomyositis – a proposed revision to the printo criteria
por: Almeida, Beverley, et al.
Publicado: (2014)

Tubuloreticular inclusions in juvenile dermatomyositis: a diagnostically useful marker?
por: Yasin, Shireena A, et al.
Publicado: (2014)

Comparison of Children With Onset of Juvenile Dermatomyositis Symptoms Before or After Their Fifth Birthday in a UK and Ireland Juvenile Dermatomyositis Cohort Study
por: Martin, N, et al.
Publicado: (2012)

Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models
por: Deakin, Claire T, et al.
Publicado: (2020)

Sub-phenotyping of juvenile dermatomyositis: can it assist clinical decisions?
por: Yasin, Shireena A, et al.
Publicado: (2014)

A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies
por: Martin, Neil, et al.
Publicado: (2011)

Driving Medical Innovation Through Interdisciplinarity: Unique Opportunities and Challenges
por: Gohar, Faekah, et al.
Publicado: (2019)

Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?
por: Tansley, Sarah L, et al.
Publicado: (2013)

Juvenile Dermatomyositis
por: Rhim, Jung Woo
Publicado: (2022)

Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis
por: Campanilho‐Marques, Raquel, et al.
Publicado: (2016)

Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis
por: Nistala, Kiran, et al.
Publicado: (2013)

Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis
por: Wilkinson, Meredyth G Ll, et al.
Publicado: (2023)

Association with HLA-DRβ1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis
por: Deakin, Claire T, et al.
Publicado: (2022)

Expression of myxovirus‐resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis
por: Soponkanaporn, S., et al.
Publicado: (2018)

Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use
por: McCann, Liza J., et al.
Publicado: (2015)

Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease
por: Varsani, Hemlata, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tdh3evd155k3vtclmjhrkpn7de